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ABSTRACT
A monoanionic, tetradentate p-diketiminate (BDI) ligand with pendant quinoline arms,
BDI 0QH was coordinated to Pt(II) to yield the square-planar complex [Pt(BD100)]CI. This
complex was characterized by NMR spectroscopy, ESI-MS, FTIR spectroscopy, UV-
Visible absorbance spectroscopy, and cyclic voltammetry. Computational studies,
including geometry optimizations and frequency calculations, were carried out to further
analyze the electronic structures of the complexes.
In addition, the DNA-binding properties of the complexes were evaluated by UV-Vis
titrations and an ethidium-bromide displacement assay. Our results indicate that the
compounds interact with DNA, although the mode of interaction is still ambiguous.
Fluorescence studies were also performed to investigate the interaction of the complex
with bovine serum albumin (BSA) as a model protein. Finally, cytotoxicity data were
obtained in a small panel of cell lines using the MTT assay. The complex has a toxicity
comparable to or higher than that of cisplatin in the lines tested.
Thesis Supervisor: Stephen J. Lippard
Title: Arthur Amos Noyes Professor of Chemistry
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INTRODUCTION
Since the discovery of its anticancer activity in the 1960s' and its implementation in the
clinic in 1978, cisplatin has experienced remarkable success as a chemotherapeutic
drug. The drug is effective against ovarian, head and neck, bladder, and cervical
cancer; notably, cisplatin has a greater than 90 percent success rate against testicular
cancer.2,3 Despite its success, cisplatin conveys numerous side effects, the most
severe of which include toxicity to the kidneys and nervous system,2 as well inherent or
developed resistance to the drug.4 Minimizing these toxicities has spurred many efforts
to find alternative therapies. These alternative platinum drugs generally aim to
circumvent cisplatin resistance, perform better than cisplatin in specific types of tumors,
or minimize harmful side effects, often at the cost of efficacy.5
The success of platinum complexes with p-diketonate ligands, as demonstrated in our
lab,6 motivated us to investigate related p-diketiminate, or nacnac, ligands as scaffolds
for new platinum anticancer agents. Whereas a p-diketonate ligand can be modified
along the carbon backbone by functionalization of the methyl groups or the y-carbon
atom, the nacnac ligands offer further versatility with an extra R group on each nitrogen
atom(Figure 1). In this manner, the R groups of the nacnac ligand can be modified with
the intention of creating a drug that acts differently than cisplatin, potentially overcoming
certain resistance mechanisms. Although there has been a renewed interest in p-
diketiminate metal complexes in the past decade, very little work has been done with
platinum or palladium complexes of these ligands7 , and the work that was done did not
investigate the biological properties of these compounds.Y'
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A nacnac derivative of particular
SN N N
interest is the ligand BDIQH N
(Figure 1), in which the R groups
Figure 1: The nacnac compound (middle) offers two new
are quinoline arms. Although this positions which can be manipulated to confer the desired
properties to the ligand. On the right is BDIQQ, the ligand
ligand was originally synthesized in investiiated in this study.
1971,11 its coordination chemistry has only recently been investigated for first row
transition metals.12"- 4 Computational data from these recent studies suggest that the
bite angle of this tetradentate ligand may be better suited for larger second and third
row transition elements.' 4 We envisioned that this flat, tetradentate ligand would give
rise to stable square-planar complexes of Pt(II). Furthermore, as extended aromatic
systems, these complexes may have the potential to interact strongly with DNA,
possibly through an intercalative mode.
In this thesis, the synthesis and characterization of the Pt(ll) complex of BDI" are
reported. This complex bears some resemblance to the well-characterized square-
planar Pt(ll) terpyridine (terpy) complexes,"' 9 which served as an informative starting
point. In addition, the complexes were subjected to a number of studies to determine
whether and how these compounds might interact with DNA. Finally, cytotoxicity
studies were carried out in several cancer cell lines.
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EXPERIMENTAL
General
All experiments were carried out in air at room temperature. Reagents and solvents
were purchased commercially and used without further purification. UV-Vis absorbance
spectra were collected with a Varian Cary 1 E spectrophotometer at 25 0C using a quartz
cuvette with a path length of 10 mm. Fourier transform infrared spectra were acquired
with a ThermoNicolet Avatar 360 spectrophotometer running OMNIC software; samples
were prepared as KBr plates. Fluorescence data were obtained with a Quanta Master
4L-format scanning spectrofluorimeter from Photon Technology International.
Measurements were taken at 25 0C using a slit width of 0.5 mm and a quartz cuvette
with a path length of 10 mm. 'H and 2D (COSY) NMR spectra were obtained using a
Bruker AVANCE-400 MHz spectrometer with a variable temperature probe. 1H and 2D
NMR chemical shifts were referenced to TMS (8=0) using the residual solvent peaks.
Chemical shifts are reported in ppm. Mass spectrometric data were collected using an
Agilent Technologies 1100 series LC-MSD trap. Electrochemical data were acquired
using a VersaSTAT3 potentiostat from Princeton Applied Research, with the V3 Studio
software. A three-electrode system was used, consisting of a silver/silver chloride
reference, a glassy carbon working electrode, and a platinum wire auxiliary electrode.
Samples were prepared as 2mM solutions in DMF with 0.1 M (n-Bu 4N)PF6 as the
supporting electrolyte. Cyclic voltammograms were obtained at a scan rate of 20 mV/s
or 100 mV/s, and the external ferrocene/ferrocenium redox couple was consistently
observed between 0.54 and 0.56 V vs. Ag/AgCI.
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Synthesis of BDI*H
The synthesis of the ligand was carried out according to the procedure previously
reported by Zatka" (Figure 2). A mixture of 349 mg (2.13 mmol) of 1,1,3,3-
..- itetramethoxypropane
O O/ HC+xes /2 3HCl and 614 mg (4.26
IN ' O N-1 55C, 5 min ' N*22NH2 methanol mmol) of 8-
1,1,3,3-Tetramethoxypropane 8-Aminoquinoline
1-(8-Quinolytamino)-3-(8-quinolylimino)-propene
Figure 2: Reaction scheme depicting the synthesis of BDIWH. The aminoquinoline 
was
product is obtained as the trihydrochloride dehydrate salt of the desired dissolved in 5 mL ofligand.
methanol to give a brown solution. This solution was heated to 55 0C, and 2.5 mL of 3.5
M HCI were added dropwise. Upon addition of the acid, the solution turned bright red.
The reaction was allowed to stir for 5 min at 55 0C and then cooled to room
temperature. A yellow solid precipitated immediately. The flask was kept at 4 0C for 45
min to further induce precipitation of the product. The orange-yellow solid, the
trihydrochloride dihydrate salt of the desired product, was collected by filtration and
washed several times with a 50-50 methanol-ether mixture to remove an orange
impurity. The product was dried overnight in a desiccator. Yield: 726 mg (73%). 1H
NMR (400 MHz, DMSO-d6): 12.67 (d, 1 H), 9.29 (t, 2H), 9.06 (dd, 2H), 8.53 (dd, 2H),
7.98 (d, 2H), 7.94 (d, 2H), 7.74 (m, 4H), 7.13 (t, 1 H). Literature values (500 MHz,
DMSO-d6) 4 : 12.65 (d, 1H), 9.23 (t, 2H), 9.06 (dd, 2H), 8.53 (dd, 2H), 7.96 (d, 2H), 7.94
(d, 2H), 7.76 (dd, 2H), 7.74 (dd, 2H), 7.13 (t, 1H). ESI-MS (positive ion mode):
calculated 325.14, found 325.2 (BD100 *). Decomposition temperature: 172 - 180 *C.
12
Synthesis of [Pt(BDI")]CI
To a suspension of 167 mg (0.356 mmol) of BDI"H in ca. 2 mL acetonitrile were added
approximately 1 mL of triethylamine in a dropwise manner, forming a homogeneous
solution. To this orange solution, 150 mg (0.355 mmol) of solid Pt(DMSO) 2Cl 220 was
added, immediately forming a brick-red suspension. The mixture was allowed to stir for
3 h and then filtered to separate the product. The red solid was filtered and washed
several times with acetonitrile and then with diethyl ether to remove any unreacted
ligand and excess base. Yield: 158 mg (80%) crude product, 80% pure by NMR. The
product can be purified further by vapor diffusion of diethyl ether into a methanol
solution, but a great deal of compound is lost in the process (27% yield). 'H NMR (400
MHz, DMSO-d6, 200C, ca. 30 pM): 9.37 (d, 2H), 8.75 (d, 2H), 8.29 (d, 2H), 8.13 (d, 2H),
7.81 (t, 2H), 7.70 (t+d, 4H), 5.59 (t, 1 H). IR (KBr, cm~'): 3433 s, 3031 vw, 2967 vw,
2919 vw, 2846 vw, 2381 w, 2349 w, 2310 vw, 1631 w, 1583 m, 1496 s, 1466 vs, 1399
m, 1384 m, 1357 w, 1331 w, 1313 s, 1279 m, 1214 w, 1134 w, 1089 w, 821 m, 803 w,
759 m, 626 vw, 581 vw, 563 vw, 531 w, 476 w. ESI-MS (positive ion mode): calculated
517.9, found 517.9 ([Pt(BDIQ)]*). UV-Visible spectrum (25 *C, DMSO+PBS, <5%
DMSO): Xmax=336 nm, E=8268.5; Xmax=540 nm, &=5129.5; Xmax=560 nm, e=5074.9. No
observable melting or decomposition up to 400 0C. Elemental analysis: calculated for
[Pt(BDIQO)]CI * 2 H20, 42.75% C, 3.25% H, 9.50% N; found, 43.03% C, 2.94% H,
9.39% N. X-ray quality crystals were obtained by vapor diffusion of diethyl ether into a
DMF solution. Spectra of the complex can be found in Appendix A.
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X-ray Crystallographic Studies
Structure determination was determined by the following protocol by Justin Wilson. A
crystal of [Pt(BD1lQ)]CI was mounted in Paratone oil on a cryoloop and frozen under a
100 K KRYOFLEX nitrogen stream. Data were obtained using a Bruker APEX CCD X-
ray diffractometer with graphite-monochromated Mo Ka radiation (X=0.71073 A)
controlled by the APEX2 software. 21 The program CellNow was used to find two
independent crystal domains, over which the data were independently integrated.
Absorption corrections were applied using TWINABS. 22 The structures were solved
with direct methods and refined on F''with the SHELXTL-97 software package.23.24
Structures were checked for higher symmetry using PLA TON.25 All non-hydrogen
atoms were located and refined anisotropically, and all hydrogen atoms were placed in
idealized locations. Structure refinement was carried out using established strategies. 26
A large solvent-accessible void remained in the crystal lattice with significant electron
density. Attempts to use the program SQUEEZE to model this disordered electron
density were unsuccessful due to the apparent incompatibility of this algorithm for non-
merohedral twinned crystals. As a result, the largest residual electron density peak is
7.6 electrons. Further information is provided in Appendix B.
Theoretical Calculations
All computational calculations were carried out using the ORCA software package. 27
Geometry optimizations, molecular orbital generations, and frequency calculations were
carried out using the BP86 functional. The generated molecular orbitals were visualized
using Gabedit. The def2-TZVP(-f) and def2-TZVP/j basis set and auxiliary basis sets
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were used in the calculations. The ZORA relativistic correction was applied to all
calculations.2 No effective core potential was applied. The absence of imaginary
frequencies ensured that the optimized geometries were local minima on the potential
energy surface.
DNA-Complex Titration
Preliminary studies of the reactions of the platinum compound with calf thymus DNA
were carried out by monitoring changes to the UV-Visible spectrum. A 10 piM sample of
the metal complex was prepared by diluting a 1 mM DMSO stock solution with PBS
(phosphate buffered saline, pH 7.3-7.5). Aliquots of calf thymus DNA (10 mg/mL) were
added to this dilution to give base pair to metal ratios ranging from 1:1 to 20:1, and the
UV-Visible spectrum was recorded following each addition.
Ethidium Bromide Competition Assay
Calf thymus DNA was incubated with ethidium bromide (12.5 piM) in the ratio [DNA base
pairs]/[EtBr] = 10 for one hour before fluorescence measurements were performed.
This solution was prepared in 5 mM Tris/50 mM NaCI buffer at pH 7.0. The stock
solution (1 mM) of the complex being tested was prepared in DMSO and added directly
to the DNA/EtBr mixture to give the desired metal concentrations (0-50 piM; all solutions
contained <5% DMSO). Fluorescence measurements were taken ten minutes after
each addition to observe the effect on EtBr fluorescence. Control scans showed that
the emission did not vary significantly with longer incubation time or repeated scans
(i.e., no bleaching effect was observed), and literature 30 reports that neither calf thymus
15
DNA nor ethidium bromide alone will give intense emission. In addition, our own
studies show that our complex does not emit in aerated aqueous buffers, as in the
conditions for this experiment.
Protein Interaction Studies31
Quantitative analyses of the interactions between bovine serum albumin (BSA) and
[Pt(BD100 )]CI were performed by fluorimetric titration. In the first trial, successive
aliquots of BSA were added to a 3.5 IM solution of [Pt(BD1lQ)]CI in PBS and allowed to
incubate for 5 minutes. After each addition, fluorescence spectra were obtained with an
excitation wavelength of 540 nm and emission monitored from 550 to 800 nm in order to
test for turn-on of the platinum complex.
A second trial was performed in which successive aliquots of [Pt(BD100 )]CI were added
to a 1.3 IM solution of BSA in PBS buffer. After each addition the tryptophan emission
of the protein was monitored by observing the fluorescence spectrum from 300 to 540
nm with an excitation wavelength of 280 nm.
Cell Lines and Culture Conditions
Human HeLa (cervical cancer) and human A549 (lung carcinoma) were grown as
adherent monolayers in Dulbecco's Modified Eagle Medium (DMEM) supplemented with
10% fetal bovine serum and 1 % penicillin/streptomycin. The cultures were grown in 25
cm2 flasks in an incubator at 370C with a humidified atmosphere composed of 5% CO2.
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Cytotoxicity Assays
The cytotoxicity of cisplatin and [Pt(BD1AQ)]CI were determined by the colorimetric MTT
assay. Cisplatin was diluted from a PBS solution. Due to the low solubility of
[Pt(BDI0 )]CI in aqueous solutions, a concentrated solution was first prepared in DMSO,
and then diluted such that the highest dose given to cells contained only 1% DMSO. In
addition, a control was performed with media having different amounts of DMSO in
order to correct for any toxicity due to the presence of the organic solvent rather than
the compound.
Trypsinized HeLa and A549 cells were seeded into a 96-well plate at a cell density of
2000 cells/well in 200 iL of growth medium and were incubated for 24 h. The wells
were then aspirated and 200 jaL of new media containing various concentrations of the
platinum complexes was added to each well. After a 72-h incubation period, the
medium was aspirated again, and a 0.8 mg/mL solution of MTT in DMEM was added.
The plate was incubated for another 4 h, aspirated, and then a 200 pL solution of 4%
ammonia in DMSO was added to each well to dissolve the purple formazan crystals.
The absorbance of the plates was read at 550 nm. Absorbance values were normalized
to platinum-free control wells and plotted as [Pt] versus % viability. IC50 values were
interpolated from the resulting curves, and the reported values are the averages from 3
independent trials for HeLa and 2 independent trials for A549, each of which consisted
of six replicates per concentration level.
17
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RESULTS AND DISCUSSION
Synthesis and Characterization
The synthesis of [Pt(BDIQQ)]CI was accomplished by the treatment of BDI0H with a
base in acetonitrile and the addition of [Pt(DMSO) 2Cl2] as a labile metal complex (Figure
3). Because the product is insoluble in acetonitrile, the reaction was carried out with a
N N N N
+ Pt(DMS0) 2(C) 2  Pt
N HACN N N
Figure 3: Reaction scheme depicting addition of BDIY to platinum.
slight excess of the soluble ligand, thereby allowing for isolation of the product by
filtration and removal of unreacted starting material with solvent washing. The platinum
complex is soluble in DMSO and DMF up to approximately 25 mM and soluble at only
low mM concentrations in methanol and water. Increasing the ionic strength of the
solvent drastically lowers the solubility, and we found the compound to be less soluble
in PBS versus DI water and DMF with (n-Bu 4N)PF6 (used for the electrochemical
studies performed) versus pure DMF.
[Pt(BD100)]CI was characterized by NMR spectroscopy and IR spectroscopy. The
platinum compound was also characterized by electrospray ionization mass
spectrometry (ESI-MS) and X-ray crystallography. The ESI-MS spectrum for
[Pt(BD100)]CI in the positive ion mode showed the expected, distinct platinum isotope
pattern at m/z 517.9, corresponding to the cationic metal complex without the chloride
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counterion. The elemental analysis suggests the presence of water in the crystal lattice
of the complex, which is also supported by the presence of unresolved solvent-
accessible voids in the X-ray structure.
In the FTIR spectra for the complex, we observe a series of medium to strong peaks
from about 1600 cm' to about 1400 cm~1, which may be due to the aromatic rings. The
spectra also shows a very strong stretch at about 1450 cm'. This value is about
midway between the range for a C-N stretch (1340-1020) and the range for a nitrile
stretch (2260-2220), and we have attributed it to the C-N stretch in the backbone of the
ligand. The Pt-N stretches occur at too low of an energy to be observed in our spectra.
Table 1: UV-Visible
Spectroscopy Data
kmax cx103 (M'cm')
[Pt(BDIQQ)]CI
336 nm 8.27 (160)
540 nm 5.13(52)
560 nm 5.07 (130)
Note: The numbers in parentheses are
the calculated standard deviations
based on three trials. Spectra used for,
calculation of. are available in
Appendix A.
UV-Visible samples were prepared by diluting a
1 mM DMSO stock solution of the platinum
complex with PBS (all samples <10% DMSO).
A high energy band is observed at 336 nm, and
two less intense, lower energy bands are
observed at 540 and 560 nm. These bands are
assigned to metal-to-ligand charge transfer
transitions. The higher energy feature is also
observed in other metal complexes with BDI",
but these other complexes show one low energy band present of the two that we
observe." [Pt(BDIl)]CI also displays considerably more bathochromic shifts
compared to the free ligand than the first row transition metal complexes synthesized by
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in previous work.14 Fluorescence measurements were also taken of [Pt(BD1aa)]CI. No
emission was observed in aerated, aqueous solution. However, weak emission is
observed in DMSO. This result suggests that water may quench the emissive excited
state.
All expected chemical shifts were present in the 1H spectra of the metal complex
(reported in the experimental section). Compared to those in the free ligand, the
chemical shifts of [Pt(BDIQQ)]CI are shifted downfield. The y-proton of the backbone
shows an upfield shift of almost 2 ppm. Unfortunately, even at max saturation in
DMSO-d6, the complex was not concentrated enough to acquire 13C or 195Pt spectra.
The chemical shifts of planar metal complexes, such as [Pt(terpy)Cl]*, depend on
concentration and temperature due to intermolecular 7n-stacking interactions.32 Because
the planar structure of [Pt(BDlaa)]CI has the potential for 71-stacking interactions, we
performed concentration- and temperature-dependent NMR spectroscopic studies.
First, 1H NMR spectra were obtained on a 0.92 mM sample of [Pt(BDIQQ)]CI at ten
degree intervals from 25 OC to 95 OC. A final spectrum was obtained at 25 0C after the
temperature variation to ensure that the original compound had not decomposed. For
the concentration-dependent study, the most concentrated sample used the same 0.92
mM sample as the temperature-dependent observations; subsequent samples were
prepared by diluting 3 parts Pt solution to 1 part DMSO-d6. The variations in chemical
shift of the y-proton of the ligand backbone are shown in Figure 4 below.
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Figure 4: Variations in chemical shift of [Pt(BDI"0)]CI due to change in concentration or temperature. As
temperature increases or concentration decreases, either of which discourage aggregation, the chemical
shifts move downfield due to a loss of the shielding environment created by stacking. The chemical shift
shown is that of the -y proton of the liqand backbone.
As the conditions favor the dissociation of aggregates, namely low concentration and
increased temperature, the chemical shifts of the complex move farther downfield. This
observation is consistent with increased shielding of the protons caused by i-stacking
interactions. We can thus conclude that the same aggregation exhibited by the
platinum terpy complexes is shared by [Pt(BDIQQ)]CI.33
Complete figures from the characterization, including 1H and COSY NMR spectra, FTIR
spectra, ESI-MS, and the UV-Visible spectra used to obtain the extinction coeffiecients
of the complexes, can be found in Appendix A.
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X-ray Crystal Structure of [Pt(BD1Q )]CI
[Pt(BDIQQ)]CI was characterized by X-ray
crystallography (Figure 5). More
N2 N3 .information about the structure, including a
full table of data collection, refinement
N1 N4
N N4 parameters, and images of the packing,
can be found in Appendix B. Bond
distances and angles involving the central
Figure 5: Molecular structure of [Pt(BDIO)]Cl platinum atom are listed in Table 2. The
Pt-N bonds, all close to 2 A, are of the expected length.
The bond distances between the Pt atom and Table 2: Selected Interatomic
Lengths (A) and Angles (deg) forNI and N4 are longer than those between the [Pt(BDIQQ)JCI
Pt and N2 and N3. This difference may be due Pt1 -N1 2.064(9)
to the stronger donation of N1 and N2, which Pt1-N2 1.996(9)
Pt1-N3 1.987(10)
bear some negative charge of the ligand Pt1-N4 2.043(9)
backbone. The compound is not perfectly N1-Ptl-N2 81.2(4)
N1-Pt1-N3 173.0(4)
planar, and the N-Pt-N angles are not 90 N-Pt-N4 104.6(4)
degrees. The bond between the platinum atom N2-Pt1-N3 93.6(4)N2-Ptl-N4 173.3(4)
and one of the quinoline nitrogens lifts up out of N3-Ptl-N4 80.9(4)
Note: The numbers in parentheses are
the plane of the complex. To quantify the the calculated standard deviations of
the last significant figures. Atoms are
deviation from planarity, the best plane for each labeled as shown in Figure 5.
quinoline arm was calculated, and the angle between these two planes was measured
23
Figure 6: The complex's deviation from planarity
was measured by finding the angle between the
planes of the two quinoline arms, as shown.
(see Figure 6). This angle is 11.770 in
this crystal. The crystal structure also
showed that the compound is arranged
into a series of columns. The closest
contacts between these stacks range
from 3.37 to 3.40 A, which is evidence of
pi stacking interactions.
Unfortunately, there was a great deal of disordered electron density in the obtained
crystal structure. This disorder is currently attributed to disordered solvent in the lattice
that was not fully resolved.
Cyclic Voltammetry
Cyclic Voltammetry: Pt(II) BDI*H
-4
D e LUMO+1
-6- LUMO
-8-
-10 HOMO1
-1 -0.5 0 0.5 1 1.5
Potential (V) vs ferrocene
Figure 7: Cyclic voltammogram of [Pt(BDIQ)]CI. Data obtained at a
scan rate of 20 mV/s from a 2mM solution in DMF with 0.1 M
(n-Bu 4N)PF6 as the supporting electrolyte.
The electrochemical
properties of
[Pt(BD100 )]CI were
investigated by cyclic
voltammetry. Because
the compound is
insoluble in an aqueous
buffer such as PBS, the
electrochemical studies
were carried out in DMF
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with (n-Bu 4N)PF6 as the supporting electrolyte. Platinum terpy complexes undergo an
irreversible oxidation and two reversible reductions.15 , 3 4 Similar electrochemical
behavior was observed for [Pt(BD100 )]CI (Figure 7). Two quasi-reversible reduction
events occur between -1.34 V and -0.93 V. These two waves have been assigned to
ligand-based redox events. The platinum displays a single irreversible oxidation peak,
much like the platinum terpy complexes, at 1.14 V. The oxidation, which we have
assigned as metal-based, appears to lead to the decomposition of the compounds.
This decomposition can be seen in the cyclic voltammograms (Appendix C), as
subsequent scans no longer have the same two reversible reduction waves. However,
scans carried out in a potential window excluding this oxidation show no significant
change in these ligand-based events (See Appendix C for more electrochemical data).
Theoretical Calculations
Geometry optimizations were performed for both metal complexes using the BP86
functional. The final optimization of the platinum complex showed an even greater
deviation from planar geometry than observed experimentally with the X-ray crystal
structure. The deviation from planarity was quantified again by finding the angle
between the planes of the quinoline arms (Figure 6). The optimized geometry of the
platinum complex gives an angle of 18.360, compared to the value of 11.770 found for
the experimentally determined structure. This deviation is still smaller than those
experimentally determined for Zn and Cu complexes of the ligand,14 which are 26.420
and 28.180, respectively.
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Figure 8: From left to right, the HOMO, LUMO, and LUMO+1 of the platinum complex. The
LUMO and LUMO+1 are ligand based, and the HOMO has some metal character.
HOMO, LUMO, and LUMO+1 for both complexes are shown in Figure 8. These orbitals
lend support our assignments of the electrochemical features observed in the cyclic
voltammogram. For instance, we previously indicated that the two quasi-reversible
reduction waves observed in the cyclic voltammogram were ligand-based redox events.
This statement implies that the LUMO and LUMO+1 should be primarily ligand-based
orbitals. This assignment is consistent with the computationally generated MO
diagrams. The LUMO and LUMO+1 comprised almost exclusively ligand-based 7i-
orbitals, with the LUMO+1 more localized to the quinoline arms and the LUMO more
spread out over the entire ligand. The oxidation, which we have assigned as metal-
based, would involve removing electrons from the HOMO. As we would expect, the
HOMO shows metal-based electron density in addition to the ligand 7c-orbitals.
A frequency calculation was also performed to ensure that the optimized geometry did
not yield any vibrations with imaginary values. This calculation predicted an IR
spectrum (Appendix D) that matched the experimentally determined one within a few
cm
26
Preliminary DNA-Binding Studies (UV-Vis)
UV-Vis: (PtBDICI with Varying Amounts of DNA
0.26_ 
-- 5e DNonDA
2 eq DNA
0.2- 5eq DNAI 10 eqDNA
20 eq DNA
0.15-
0.1
0.056
250 300 350 400 450 500 550 600 650
Wavelength (nm)
Figure 9: UV-Visible spectra of [Pt(BD144)]CI in the presence of
increasing concentrations of DNA (PBS buffer, 1% DMSO). The
concentration of the complex was 10 pM, and DNA concentrations
ranged from 1 to 20 base pairs per metal.
The bold black line in
the absence of DNA.
0C-)
0I
450 600 55
Figure 10: Excitation
[Pt(BD100 )]CI in the pres
present at concentration
DMSO). The compound
The interactions of
[Pt(BDIoa)]CI with calf thymus
DNA were investigated by
UV-Vis spectroscopy. Upon
the addition of increasing
amounts of CT-DNA to
[Pt(BDIQQ)]CI, significant
changes in the UV-Vis
spectrum are observed.
Figure 9 shows the absorption spectrum of the metal complex in
A slight bathochromic shift and hyperchromicity of the absorbance
bands occurs upon the
(PtBDI*)CI + 20 eq. DNA addition of increasing
- Emission: 560
- Excitation: 680
amounts of DNA. The
lowest energy band, at
560 nm, undergoes the
largest increase in
absorbance. Whereas
0 600 50 700 750 Boo a red shift in
Wavelength
(purple) and emission (red) spectra for
ence of 20 equivalents of DNA. [Pt(BDIQQ)]CI absorbance bands is a
of 10 pM with 20 bp of DNA/metal in PBS (1%
emits at 680 nm. common marker of
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intercalation, hyperchromicity is not. 17, a For confirmed metallointercalators,
hypochromic shifts are observed exclusively. The fact that a hyperchromic shift is
observed suggests that a different mode of DNA interaction may be operative. Others
have attributed hyperchromic shifts to groove binding or electrostatic DNA
interaction S.3
The emission properties of [Pt(BDIQQ)]CI in the presence of 20 equivalents bp of DNA
were investigated. As mentioned previously, in the absence of DNA the complex is not
emissive in aerated aqueous buffer. As shown in Figure 10, however, the platinum
complex in the presence of DNA exhibits an emission band centered at 680 nm upon
excitation at 560 nm. Although the emission signal is fairly weak, it increases upon
addition of more DNA. The red emission and large Stokes shift (120 nm) suggest that
this emission originates from a triplet excited state. These properties may be useful for
cellular imaging studies.
Ethidium Bromide Competition Assay
Ethidium bromide in aqueous solution is not emissive. In the presence of DNA,
however, it is strongly emissive as a result of its intercalative interaction with DNA.
Other DNA-binding agents can compete for ethidium-binding positions, resulting in a
decrease of fluorescence intensity. This change in intensity can be used to estimate an
apparent binding constant for the competing agent.
28
X 106 Effect of Increased (PtBDPO)CI on Ethidium Bromide Fluorescence
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Figure 11: (Left) Emission spectrum of EtBr+DNA [DNA base pairs]/ [EtBr]=10, [EtBr]=12.5 pM) in the
presence of increasing concentrations of [Pt(BDI )]CI. (Right) Plot of platinum concentration versus
(1/L). The plot shows that half of the EtBr is displaced with a platinum concentration of about 30 pM.
Ethidium bromide and DNA were incubated in pH 7.0 Tris buffer for one hour at a ratio
of [DNA base pairs]/[EtBr]=10. Following this incubation, [Pt(BDIQ0)]CI was added in
concentrations from 0-50 pM and the mixture was allowed to equilibrate for ten minutes
before measuring the emission spectra by excitation at 518 nm (Figure 11).
The equation,
KEtBr [EtBr] = Kapp [[Pt(BD100 )]CI] 35
where KEtBr= 4 .94 x 105 M-1, [EtBr]=12.12 pM, (adjusted from initial concentration of 12.5
pM to account for extra volume added with Pt aliquots) and [[Pt(BDIQ0 )]Cl]=the
concentration of the complex at which 1/10=0.5, can be used to calculate an apparent
binding constant for the complex. The apparent binding constant of [Pt(BDIQQ)]CI is
approximately 2 x 105 M-1. In a similar assay performed on a number of copper
complexes, the compounds that the authors concluded to be intercalators showed
apparent binding constants of 0.7, 1.3, and 3.4 x 105 M1. The apparent binding
constant found for [Pt(BDIQQ)]CI is on the same order of magnitude of that for ethidium
bromide, and even higher than the reported value for some confirmed intercalators.
Therefore, [Pt(BD144)]CI interacts strongly with DNA relative to other noncovalently
interacting complexes.
Protein Interaction Studies
04 BSA Interaction: Monitoring Pt Emission The emission turn-
Pt only
4.s - -- 1.4 BSA Pt- on of [Pt(BDIQQ)]CI
- 2.9 BSA: Pt
7 -SA Pt in the presence of
3.5- 7517BSA:Pt7.1 BSA: Pt
3 214 BSA Pt DNA prompted us to28.6 BSA: Pt
investigate whether
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v.5 similarly induce a
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Figure 12: Emission spectrum of [Pt(BDI4)]CI in the presence of increasing serum albumin is the
concentration of bovine serum albumin (BSA) in PBS. The platinum complex
does not show turn-on even in the presence of >25x excess of protein. most abundant
protein in human plasma. Interaction studies were performed with bovine serum
albumin (BSA) as an analog to human serum albumin in order to determine whether the
turn-on would be accomplished by interaction with any large biomolecule, or whether it
was more specific to DNA. Two titrations were carried out with BSA and [Pt(BD100 )]CI.
First, aliquots of BSA were titrated into a solution of the platinum complex. Spectra
were taken after each addition, monitoring emission from 550 to 800 nm with an
excitation wavelength of 540 nm in order to observe any emission from the platinum
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complex. Increased concentration of BSA in the solution does not induce emission of
the platinum complex; as can be seen in Figure 12; the emission spectrum stays near
the baseline.
5 1 BSA Interaction: Monitoring Protein (Trp) Emission After it was
-Protein Only
-111 BSA"P determined that the
-- 5.6 BSA: Pt
2 - -- 3.7 BSA: P1
2.8 BSA:Pt presence of the
2.2 BSA:Pt
-- 1.1 BSA: Pt
0.7 BSA Pt protein was not
-- 0.6 BSA: Pt
causing the complex
to emit, another
0.s
titration was carried
30 350 400 450 out to determine if
Wavelength (nm)
Figure 13: Emission spectrum of tryptophan in BSA. As platinum the complex and
concentration increases, tryptophan emission is quenched due to interaction
between the complex and the protein. the protein were
interacting at all. For this titration, successive aliquots of [Pt(BDIQQ)]CI were added to a
solution of BSA in PBS buffer. The protein was monitored by observing the
fluorescence intensity of its tryptophan residues; emission was measured from 300 to
450 nm after exciting at 280 nm. The results are shown in Figure 13; increasing the
concentration of the platinum complex decreases the emission observed from
tryptophan, thereby indicating that the complex and the protein interact. The evidence
for complex interaction with BSA without emission suggests that the turn-on may be
specific to interaction with DNA. The nature of the complex: BSA interaction might not
be sufficient to protect the complex from water or oxygen, which may quench the triplet
31
excited state. The apparent emission
selectivity of the complex for DNA
over proteins
may be of use for imaging cellular
DNA.
Table 3: ICso(pM) Determined by MTT
HeLa A549
[Pt(BD100)]Cl 2.82(1.66) 1.23(0.22)
cisplatin 2.29(1.4) 5.23(1.01)
Cytotoxicity Studies
HeLa viability = cisPt
e (PtBDIQQ)CI
a
a
0
5
Concentraton (uM)
A549 Viability
Concentration (uM)
10
* cisPt
* (PtBDIQQ)CI
S
12
The cytotoxicities of [Pt(BD100 )]CI and
cisplatin were measured in human lung
carcinoma (A549) and human cervical
cancer (HeLa) cell lines using the
colorimetric MTT assay. Because our
platinum complex has low solubility in
aqueous buffers, it was dissolved in
DMSO and then diluted in growth
media. Cell viability values were
corrected to a DMSO-only control plate
in order to ensure any cytotoxic effect
was due only to the platinum complex.
The IC50 values of the two compounds
in the cell lines tested can be seen in
Table 3. Reported errors, in
parentheses, are standard deviations of
mS
*
0
100 -
50-
0-
100-
50-
0-.
QU
q
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Figure 14: Cell viability curves for [Pt(BDl"")]Cl and
cisplatin in HeLa (top) and A549 (bottom). Viability
values found for [Pt(BD1 0Q)]CI are corrected to
account for cell death due to DMSO in media.
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>2 independent trials. Dose-response curves are shown in Figure 14.
These studies show that [Pt(BDI")]CI exhibits cytotoxicity similar to that of cisplatin in
the HeLa cell line, and is four times more toxic than cisplatin in the A549 line.
Therefore, [Pt(BD1IQ)]CI is a potent cytotoxic agent. The mechanism of action,
however, remains unclear and should be the focus of future studies.
33
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CONCLUSIONS AND FUTURE WORK
The synthesis of a new Pt(II) complex of BD1lQ is described. The platinum metal seems
better able to accommodate the large, inflexible ligand; although the compound is not
planar, it does show a smaller deviation from planarity than complexes with smaller
metal centers. The electronic structure of the complex displays a number of similarities
to the well-characterized square-planar platinum terpyridine complexes. The complex
has a relatively high affinity for DNA. The precise mode of interaction with DNA,
however, remains unclear. The emission turn-on in the presence of DNA may be useful
for cellular imaging studies, and protein interaction studies suggest that the turn-on may
be DNA-specific.
The complex [Pt(BD1lQ)]CI has cytotoxicity comparable to or better than that of cisplatin
in the two cell lines tested. We are currently in the process of culturing MRC-5 cells,
normal human lung fibroblasts, in order to determine whether there is any selectivity for
cancerous over noncancerous tissue. It may also be valuable to expand the panel of
cell lines to include more types of cancer, given the promising results obtained in other
lines tested thus far.
There are a variety of experiments that can be carried out to further characterize this
compound. Because our compound may be capable of acting as a drug that can image
itself, it may prove useful to carry out further photophysical studies of the complex,
including finding the quantum yield and studying fluorescent properties in the absence
of air. In addition, further studies can be carried out to determine more precise binding
35
constants for the interaction with DNA. There are also additional experiments, such as
CD spectroscopic studies and a superhelical DNA unwinding assay, which could give
further insight as to the mode of interaction of the complex with DNA.
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APPENDIX A: PHYSICAL CHARACTERIZATION
ESI-MS of [PtBDI00]CI
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UV-Visible Absorbance Spectrum of [PtBDIQQ]CI
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APPENDIX B: SUPPLEMENTAL X-RAY DIFFRACTION DATA
Table B1. Crystal data and structure
Identification code
Empirical formula
Formula weight
Temperature
Wavelength
Crystal system
Space group
Unit cell dimensions
Volume
Z
Density (calculated)
Absorption coefficient
F(000)
Crystal size
Theta range for data collection
Index ranges
Reflections collected
Independent reflections
Completeness to theta = 30.13*
Absorption correction
Max. and min. transmission
Refinement method
Data / restraints / parameters
Goodness-of-fit on F2
Final R indices [l>2sigma(l)]
R indices (all data)
Largest diff. peak and hole
refinement for [PtBDI 00 ]CI, 2.
[PtBDIQ]CI
C21 H15 CI N4 Pt
553.91
100(2) K
0.71073 A
Monoclinic
C2/c
a = 28.380(8) A
b = 6.779(2) A p= 116.762(4)*.
c = 25.638(8) A
4404(2) A3
8
1.671 Mg/m3
6.505 mm- 1
2112
0.25 x 0.08 x 0.04 mm3
1.61 to 30.13*.
-39<=h<=35, 0<=k<=9, 0<=l<=35
6990
6990 [R(int) = 0.0000]
97.5 %
Twinabs
0.7809 and 0.2931
Full-matrix least-squares on F2
6990 / 251 / 249
1.076'
R1" = 0.0720, wR2"' = 0.2088
R1 = 0.1023, wR2 = 0.2240
7.593 and -3.050 e.A-3
i GOF = {I[w(Fo2 - Fe2)2]/(n - p)} 1/2, where n is
parameters
R1 =I IF 01 - |F| I/IFoI
wR2 = {I[w(F02 - F2][W(FO2)2])a
the number of data and p is the number of refined
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Table B2. Bond lengths [A] and angles [] for [PtBDI 00]CI, 2.
Pt(1)-N(3) 1.987(10)
Pt(l)-N(2) 1.996(9)
Pt(1)-N(4) 2.043(9)
Pt(1)-N(1) 2.064(9)
N(2)-C(1 0) 1.306(15)
N(2)-C(8) 1.422(15)
N(3)-C(1 2) 1.345(14)
N(3)-C(13) 1.415(14)
N(1)-C(1) 1.322(14)
N(1)-C(9) 1.381(13)
C(8)-C(7) 1.393(15)
C(8)-C(9) 1.428(15)
C(1 7)-C(1 8) 1.401(15)
C(1 7)-C(1 9) 1.425(17)
C(1 7)-C(1 6) 1.429(17)
C(9)-C(4) 1.398(16)
C(7)-C(6) 1.416(18)
C(6)-C(5) 1.373(18)
C(1 3)-C(1 8) 1.388(16)
C(13)-C(14) 1.412(16)
C(1 6)-C(1 5) 1.383(18)
C(21)-N(4) 1.343(14)
C(21)-C(20) 1.423(16)
C(1)-C(2) 1.392(17)
C(14)-C(15) 1.405(17)
C(10)-C(11) 1.427(18)
C(1 9)-C(20) 1.365(19)
C(1 2)-C(1 1) 1.361(17)
C(5)-C(4) 1.439(15)
C(2)-C(3) 1.381(17)
C(4)-C(3) 1.404(17)
N(4)-C(1 8) 1.402(16)
N(3)-Pt(1)-N(2) 93.6(4)
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N(3)-Pt(1)-N(4) 80.9(4)
N(2)-Pt(1)-N(4) 173.3(4)
N(3)-Pt(1)-N(1) 173.0(4)
N(2)-Pt(1)-N(1) 81.2(4)
N(4)-Pt(1)-N(1) 104.6(4)
C(1 0)-N(2)-C(8) 120.5(10)
C(1 0)-N(2)-Pt(1) 125.0(9)
C(8)-N(2)-Pt(1) 114.5(7)
C(1 2)-N(3)-C(1 3) 122.6(10)
C(1 2)-N(3)-Pt(1) 123.3(8)
C(13)-N(3)-Pt(1) 114.1(7)
C(1)-N(1)-C(9) 116.9(10)
C(1)-N(1)-Pt(1) 129.9(8)
C(9)-N(1)-Pt(1) 113.1(7)
C(7)-C(8)-N(2) 126.5(10)
C(7)-C(8)-C(9) 118.5(11)
N(2)-C(8)-C(9) 115.0(9)
C(1 8)-C(1 7)-C(1 9) 118.6(11)
C(1 8)-C(1 7)-C(1 6) 119.1(11)
C(1 9)-C(1 7)-C(1 6) 122.3(11)
N(1)-C(9)-C(4) 122.3(10)
N(1)-C(9)-C(8) 116.3(10)
C(4)-C(9)-C(8) 121.4(10)
C(8)-C(7)-C(6) 120.7(11)
C(5)-C(6)-C(7) 120.6(11)
C(1 8)-C(1 3)-C(1 4) 119.3(11)
C(1 8)-C(1 3)-N(3) 115.7(10)
C(1 4)-C(1 3)-N(3) 125.0(11)
C(1 5)-C(1 6)-C(1 7) 118.8(11)
N(4)-C(21)-C(20) 122.8(12)
N(1)-C(1)-C(2) 124.0(11)
C(1 5)-C(1 4)-C(1 3) 119.2(11)
N(2)-C(1 0)-C(1 1) 124.4(11)
C(20)-C(1 9)-C(1 7) 118.8(11)
N(3)-C(1 2)-C(1 1) 126.2(12)
C(6)-C(5)-C(4) 120.4(11)
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C(1 2)-C( 1)-C(1 0) 127.0(11)
C(16)-C(15)-C(14) 121.8(11)
C(1 9)-C(20)-C(21) 120.2(12)
C(3)-C(2)-C(1) 119.7(11)
C(9)-C(4)-C(3) 119.0(10)
C(9)-C(4)-C(5) 118.4(10)
C(3)-C(4)-C(5) 122.6(11)
C(2)-C(3)-C(4) 117.9(11)
C(21)-N(4)-C(1 8) 117.1(9)
C(21)-N(4)-Pt(1) 130.2(8)
C(18)-N(4)-Pt(1) 112.7(7)
C(1 3)-C(1 8)-C(1 7) 121.5(11)
C(13)-C(18)-N(4) 115.9(10)
C(1 7)-C(1 8)-N(4) 122.5(10)
Symmetry transformations used to generate equivalent atoms:
Table B3. Anisotropic displacement parameters (A2x 103) for [PtBDI00 ]CI, 2. The
anisotropic
displacement factor exponent takes the form: -2p2 [ h2a*2 U11 + ... + 2 h k a* b* U12 ]
U11  U22  U33 U23 U13  U12
Pt(1) 19(1) 14(1) 15(1) -1 (1) 8(1) 0(1)
N(2) 24(4) 11(4) 23(4) -3(4) 13(3) 1(4)
N(3) 24(4) 19(4) 18(4) 0(4) 13(3) 5(4)
N(1) 21(4) 13(5) 16(3) -1(3) 7(3) 1(3)
C(8) 20(4) 14(4) 23(4) -2(4) 9(3) 0(4)
C(17) 22(4) 16(5) 24(4) 3(4) 7(4) 1(4)
C(9) 22(4) 3(5) 24(4) -1(3) 10(3) -2(3)
C(7) 22(4) 26(5) 27(5) 3(5) 11(4) 2(5)
C(6) 21(5) 25(6) 32(6) -1(5) 7(4) 1(4)
C(13) 25(4) 10(5) 20(4) 3(4) 8(3) 3(4)
C(16) 26(3) 2(4) 28(4) 2(2) 5(3) 2(2)
C(21) 21(4) 17(6) 27(5) 0(4) 14(4) 0(4)
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C(1) 25(5) 26(6) 21(5) 0(4) 13(4) -1(4)
C(14) 35(5) 6(5) 23(5) -3(4) 10(4) 1(4)
C(10) 30(5) 10(5) 26(5) 0(4) 16(4) 0(4)
C(19) 24(5) 23(5) 31(5) 3(5) 13(4) 1(4)
C(12) 32(5) 27(6) 21(5) 0(4) 17(4) 5(5)
C(5) 26(3) 2(4) 28(4) 2(2) 5(3) 2(2)
C(11) 29(5) 29(7) 21(5) 2(4) 14(4) 1(4)
C(15) 30(5) 15(5) 23(5) 1(4) 6(4) -2(4)
C(20) 21(5) 27(7) 32(5) 2(5) 13(5) 2(4)
C(2) 32(5) 32(6) 22(5) 1(5) 17(4) 4(5)
C(4) 23(4) 9(5) 25(5) 3(4) 9(4) 4(3)
C(3) 31(5) 18(5) 21(5) 0(4) 8(4) 0(4)
N(4) 18(3) 17(4) 21(4) -4(4) 10(3) -2(3)
C(18) 22(4) 9(4) 28(4) 3(4) 12(3) 1(4)
Cl(1) 42(3) 53(4) 29(3) 0(2) 14(3) 11(3)
CI(2) 68(7) 62(7) 41(6) 1(4) 35(5) 5(5)
Example of pi stacking in crystal lattice; green ellipsoids show the Cl- counterion
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APPENDIX C: ELECTROCHEMICAL DATA
Cyclic voltammograms of [PtBD10Q]CI
x 10- Electrochemistry, Compound 2 (with Ferrocene Standard)
Potential
Ligand Based Electrochemistry, Compound 2
-1 -0.5 0
Potential
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APPENDIX D: THEORETICAL CALCULATIONS
Predicted IR spectrum of [PtBDIQ]CI
3125. 2778. 2431. 2083. 1736. 1389. 1041.347/2.
-75.4 -
15.08
105.6
196.11
286.6
377.2-
467.7
558.2
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829.8 '
3472.
694.5 347.2 0.000
-15.08
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1389. 1041. 694.5 347.2 0.000
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